Core Viewpoint - 康臣药业's stock price has seen a significant increase, reaching a high of 19.49 HKD, following its inclusion in the Hang Seng Composite Index, which is expected to enhance its market visibility and liquidity [1] Group 1: Stock Performance - 康臣药业's stock price rose by 6.97%, trading at 19.35 HKD with a transaction volume of 37.8752 million HKD [1] - The stock experienced an intraday increase of over 7%, marking a new high [1] Group 2: Index Inclusion - On February 13, the Hang Seng Index Company announced that 康臣药业 will be included in the Hang Seng Composite Index, effective March 9, 2026 [1] - This inclusion is anticipated to lead to adjustments in the Hong Kong Stock Connect investment scope, as 康臣药业 meets various criteria such as market capitalization, liquidity, and listing duration [1] Group 3: Share Buyback Plan - 康臣药业's board has approved an additional share buyback plan, allocating up to 100 million HKD for repurchasing shares in the open market, on top of a previous buyback plan [1] - The total funds earmarked for the share buyback plan will not exceed 300 million HKD, reflecting the board's confidence in the company's business development and future prospects [1]
康臣药业午前涨逾7%创新高 获纳入恒生综合指数